A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Verastem, Inc.
Servier
Pfizer
Eli Lilly and Company
Pfizer
Merck Sharp & Dohme LLC
Novartis
Janssen Research & Development, LLC
Janssen Research & Development, LLC
Bristol-Myers Squibb
Pfizer
Seagen Inc.
Fate Therapeutics
Alterome Therapeutics, Inc.
Novartis
Revolution Medicines, Inc.
Hoffmann-La Roche
Revolution Medicines, Inc.
Erasca, Inc.
Erasca, Inc.
Incyte Corporation
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
AstraZeneca
Incyte Corporation
Multitude Therapeutics Inc.
Pfizer
Tizona Therapeutics, Inc
Genentech, Inc.
Revolution Medicines, Inc.
PAQ Therapeutics, Inc.
Bristol-Myers Squibb
Genfleet Therapeutics (Shanghai) Inc.
Genentech, Inc.
Bristol-Myers Squibb
Mirati Therapeutics Inc.
Eli Lilly and Company
Sanofi
Pfizer
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Sotio Biotech Inc.
Bristol-Myers Squibb
Kumquat Biosciences Inc.
Nektar Therapeutics
Menarini Group
Pierre Fabre Medicament
HiberCell, Inc.
ImmunityBio, Inc.
Mirati Therapeutics Inc.
ImmunityBio, Inc.